ALTO-100

Alto Neuroscience's ALTO-300, a novel biomarker-based antidepressant, advances in Phase 2b trial for Major Depressive Disorder with topline results expected by mid-2026.

Johnson & Johnson's Spravato, an esketamine-based nasal spray, marked the first new depression medication in decades, offering a more rapid treatment option than traditional SSRIs.

Alto Neuroscience's ALTO-100, designed to upregulate BDNF, did not meet the primary endpoint in a Phase 2b trial for major depressive disorder.

Alto Neuroscience's ALTO-100 failed to meet its primary endpoint in a Phase 2b trial for major depressive disorder (MDD), as measured by the MADRS scale.